PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Alfredo Addeo, Giuseppe Luigi Banna


We have read with great interest our Colleagues’ point of view suggesting that immunotherapy should not be integrated into the treatment of oncogene-driven non-small cell lung cancers (NSCLCs) based on currently available evidence. However, we would like to mention three points to challenge their recommendation.